Which one is more effective and safer than Almonertinib or Osimertinib?

Almonertinib (Almonertinib) and osimertinib (Osimertinib) both target epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) third-generation oral EGFRtyrosine kinase inhibitors (TKI), which are mainly used to treat patients with EGFR sensitive mutations, especially relapse or progression cases with T790M resistance mutations. Although the mechanisms of action of the two are similar, there are still certain differences in clinical efficacy, safety, resistance patterns and patient indications. Comprehensive analysis is required to determine which drug is more suitable for specific patients.

From the perspective of efficacy, osimertinib, as a representative drug of the third generation EGFR-TKI, has been verified in multiple global multi-center clinical trials to have significant efficacy in patients with EGFR sensitive mutations and T790M mutations. According to the FLAURA study, osimertinib can significantly prolong progression-free survival (PFSEGFR mutated NSCLC patients pan>), the median PFS can reach 18.9 months, and the overall survival (OS) is also significantly better than the first generation TKI. Data from domestic clinical trials of Ametinib show that for patients with EGFR T790M mutation recurrence or progression, its objective response rate (ORR) and median progression-free survival have reached comparable levels, and it has shown good central nervous system penetration in patients with brain metastases. Overall, the efficacy of the two is similar, but osimertinib has more sufficient data accumulated in international multi-center large-sample studies.

In terms of safety, both ametinib and osimertinib are characterized by good tolerance, but still have different side effect profiles. Common side effects of osimertinib include rash, diarrhea, thrombocytopenia and mild cardiac function changes, most of which are 1~2level, which can be alleviated through symptomatic treatment. Domestic clinical trials of ametinib have shown that the main adverse reactions are rash, platelet decline and mild liver function abnormalities, and the incidence of serious adverse events is lower than some trial data of osimertinib. It is worth noting that the tolerability of ametinib shows certain advantages in the Asian population, especially when it is used continuously for a long time, patients have higher drug compliance.

In terms of clinical application and accessibility, ametinib, as a domestic third-generation EGFR-TKI, has been launched in China and is included in medical insurance. The price is about more than 1,000 yuan. Patients can obtain it in domestic pharmacies and hospitals, and the financial burden is relatively light. Osimertinib is also available in China, but the price is relatively high, and there are regional differences in medical insurance reimbursement policies, which may limit the accessibility of some patients. In addition, evidence is still accumulating on their efficacy, resistance mechanisms, and combination therapy in patients with brain metastases. Clinical selection should be based on the patient's individual situation, mutation type, economic conditions, and previous treatment history.

In summary, ametinib and osimertinib have their own advantages in efficacy and safety. Osimertinib has more sufficient efficacy data in international large-sample studies, especially in first-line treatment, showing significant advantages; ametinib has shown good tolerability and cost advantages in the domestic patient population, and its efficacy is similar to osimertinib. Clinical selection should be based on the patient's specific situation, mutation type, presence of brain metastasis, and economic conditions. Individualized medication can achieve the best therapeutic effect.

Reference link:https://www.drugs.com